Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Breaking Therapy Resistance: An Update On Oncolytic Newcastle Disease Virus For Improvements Of Cancer Therapy

V. Schirrmacher, S. V. Van Gool, Wilfried Stuecker
Published 2019 · Medicine, Biology

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11 described immune stimulatory properties. Fifty years of clinical application of NDV give witness to the high safety profile of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certificate for the production of a dendritic cell vaccine loaded with tumor antigens from a lysate of patient-derived tumor cells together with immunological danger signals from NDV for intracutaneous application. This update includes single case reports and retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors.
This paper references
10.3390/v7062756
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
P. Buijs (2015)
10.3390/ijms18071479
Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer
H. Tazawa (2017)
10.1016/j.ymthe.2018.01.019
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Jacob M Ricca (2018)
10.3791/58651
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo.
Johannes P W Heidbuechel (2019)
10.3390/ijms18061108
Epigenetic Strategies to Boost Cancer Immunotherapies
M. J. Barrero (2017)
10.1016/bs.ai.2015.12.002
Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.
Etienne Becht (2016)
10.1016/j.omto.2018.02.001
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
N. Annels (2018)
10.3892/IJO.14.2.205
Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures.
V. Schirrmacher (1999)
10.1002/ijc.29202
Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death
C. Koks (2015)
10.3892/IJO.29.6.1359
In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
H. Bian (2006)
10.1016/j.bbrc.2012.07.056
Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vaccine in the gut-mucosa.
M. Shoji (2012)
10.3892/ijo.2014.2692
Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study.
V. Schirrmacher (2015)
10.1158/1078-0432.CCR-12-3588
DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant Gliomas
Kazuo Okemoto (2013)
10.1016/j.cell.2017.08.027
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
A. Ribas (2017)
10.3892/IJO.21.4.685
Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients.
L. Bai (2002)
10.1097/00007890-200203270-00031
Dendritic cells cross-presenting viral antigens derived from autologous cells as a sensitive tool for visualization of human cytomegalovirus-reactive CD8+ T cells.
M. Raftery (2002)
10.18632/oncotarget.25614
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
A. Oseledchyk (2018)
10.1517/14712598.2015.1088000
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
V. Schirrmacher (2015)
10.1128/JVI.01537-10
Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells
M. Mansour (2011)
Immune contexture, immunoscore, and malignant cell subgroups for prognostic and theranostic classification of cancers
E. Becht (2016)
10.1016/S0065-230X(01)82004-2
Nitric oxide-induced apoptosis in tumor cells.
V. Umansky (2001)
10.1002/ijc.21390
A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
C. Haas (2006)
10.1158/2326-6066.CIR-14-0220-T
Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor
S. Tähtinen (2015)
10.1128/JVI.00770-17
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase
U. Rangaswamy (2017)
Attenuated veterinary virus vaccine for the treatment of cancer.
L. K. Csatary (1993)
10.3892/IJO_00000223
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus.
Holger Wilden (2009)
10.1007/s00109-002-0339-1
Stimulation of human natural interferon-α response via paramyxovirus hemagglutinin lectin-cell interaction
Jinyang Zeng (2002)
10.4161/21624011.2014.968434
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
I. Adkins (2014)
10.3892/IJO_00000221
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus.
C. Pfirschke (2009)
10.1007/978-1-4939-6964-7_10
Reverse Genetics of Newcastle Disease Virus
S. Cardenas-Garcia (2017)
10.3892/IJO.31.5.1009
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
L. Apostolidis (2007)
10.1016/j.canlet.2011.11.008
Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo.
S. Meng (2012)
10.1006/VIRO.2002.1413
Induction of Interferon-α and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Human Blood Mononuclear Cells by Hemagglutinin-Neuraminidase but Not F Protein of Newcastle Disease Virus
Jinyang Zeng (2002)
10.1128/JB.92.3.792-.1966
Tumor immunity after viral oncolysis.
W. Cassel (1966)
10.1016/j.virusres.2017.03.003
Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.
X. Xu (2017)
10.1126/scitranslmed.3008095
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
D. Zamarin (2014)
Epigenetic strategies to boost cancer
M. J. Barrero (2017)
10.21873/anticanres.12963
A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11
B. Wang (2018)
10.1016/j.imbio.2010.10.003
IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.
L. Lattanzi (2011)
10.1016/j.ccell.2018.03.011
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines.
S. Russell (2018)
10.2217/imt-2019-0033
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.
S. Raman (2019)
10.3791/50830
Rescue of recombinant Newcastle disease virus from cDNA.
J. Ayllón (2013)
10.1038/mt.2008.181
Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy
Adam Vigil (2008)
Enhancement of the proapoptotic properties of newcastle disease virus promotes remission in syngeneic murine cancer
S. Cuadrado-Castano (2015)
10.1080/1042819031000149368
Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation
D. Tough (2004)
Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus.
P. Fournier (2009)
10.1182/BLOOD.V93.7.2342.407K09_2342_2352
Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release.
A. Ushmorov (1999)
10.1186/s40425-019-0682-1
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
S. Thomas (2019)
10.1080/21505594.2018.1449507
Importin α5 negatively regulates importin β1-mediated nuclear import of Newcastle disease virus matrix protein and viral replication and pathogenicity in chicken fibroblasts
Zhiqiang Duan (2018)
10.1016/j.omto.2018.04.004
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity
Iris Scherwitzl (2018)
10.1038/sj.gt.3303095
Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes
F. Puehler (2008)
10.1016/j.it.2017.05.006
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.
Abhishek D Garg (2017)
10.1038/mt.2009.231
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
J. Altomonte (2010)
10.1128/JVI.02394-12
Prostate-Specific Antigen-Retargeted Recombinant Newcastle Disease Virus for Prostate Cancer Virotherapy
R. Shobana (2013)
10.1038/mt.2011.113
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
V. Cerullo (2011)
10.1186/s13567-019-0654-y
Hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus cooperatively disturb fusion–fission homeostasis to enhance mitochondrial function by activating the unfolded protein response of endoplasmic reticulum and mitochondrial stress
S. Ren (2019)
10.1158/0008-5472.CAN-04-1545
Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells
J. Karcher (2004)
10.1007/s00705-010-0898-3
Construction of a minigenome rescue system for Newcastle disease virus strain Italien
H. Feng (2010)
10.26420/AUSTINONCOLCASEREP.1006.2017
A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination – A Review
Schirrmacher Volker (2017)
10.3892/ijo.2011.1222
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus.
P. Fournier (2012)
10.3892/IJO.26.2.431
Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
H. Bian (2005)
10.3389/fonc.2014.00337
Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
V. Schirrmacher (2014)
10.3390/v11060527
Exosomes Carry microRNAs into Neighboring Cells to Promote Diffusive Infection of Newcastle Disease Virus
Changluan Zhou (2019)
10.3389/fmicb.2019.00209
Inhibitor of Sarco/Endoplasmic Reticulum Calcium-ATPase Impairs Multiple Steps of Paramyxovirus Replication
N. Kumar (2019)
10.1158/0008-5472.CAN-11-2975
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
I. Diaconu (2012)
10.3390/v8010009
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
A. Marchini (2016)
10.1200/jco.1997.15.7.2763
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer.
T. Ahlert (1997)
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer
R. Shobana (2013)
10.1128/JVI.03276-13
VSV-GP: a Potent Viral Vaccine Vector That Boosts the Immune Response upon Repeated Applications
R. Tober (2014)
10.1038/onc.2009.507
Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
J. Puhlmann (2010)
10.1007/978-1-61779-095-9
Viral Vectors for Gene Therapy
O. Merten (2011)
10.3892/ol.2018.8785
Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells.
Lianjing Zhao (2018)
10.1007/BF00058060
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity
V. Schirrmacher (2004)
10.1002/EJI.1830180803
Modification of tumor cells by a low dose of Newcastle Disease Virus.
Paul Von Hoegen (1989)
10.1172/JCI98047
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
D. Zamarin (2018)
10.1126/scitranslmed.aao1641
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
M. Bourgeois-Daigneault (2018)
Newcastle disease virus infection induces B71/B7-2-independent T-cell costimulatory activity in human melanoma cells
C. C. Termeer (2000)
10.1016/0959-8049(95)96247-B
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
D. Ockert (1996)
10.1023/B:NEON.0000021735.85511.05
MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas
L.K. Csatary (2004)
10.1089/jir.2019.0037
Fueling Type I Interferonopathies: Regulation and Function of Type I Interferon Antiviral Responses.
Chen Seng Ng (2019)
10.1038/s41598-018-29929-y
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo
Y. Bai (2018)
10.1007/s40259-012-0008-z
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
P. Fournier (2012)
10.1016/J.IMMUNI.2007.03.006
Dendritic cells prime natural killer cells by trans-presenting interleukin 15.
Mathias Lucas (2007)
Newcastle disease virus as an antineoplastic agent. Cancer
W A Cassel (1965)
Review of its mechanism of action and clinical efficacy and safety
S S Raman (2019)
10.1080/2162402X.2018.1442169
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
S. Gujar (2018)
10.1089/jir.2019.0015
Endogenous Nucleic Acid Recognition by RIG-I-Like Receptors and cGAS.
J. Lee (2019)
10.1186/s12943-017-0596-9
Epigenetics in cancer stem cells
Tan Boon Toh (2017)
10.3389/fonc.2014.00224
Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies
V. Schirrmacher (2014)
10.1172/jci.insight.124989
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.
Yana G. Najjar (2019)
10.1016/j.meegid.2019.103917
Updated unified phylogenetic classification system and revised nomenclature for Newcastle disease virus
K. Dimitrov (2019)
10.4161/cbt.29686
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy
Fu-liang Bai (2014)
10.1007/978-1-61779-340-0_13
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
P. Fournier (2012)
10.3390/biomedicines4030016
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
V. Schirrmacher (2016)
Bian, H. α2,6-linked sialic acid serves as a high-affinity receptor for cancer Oncolytic virotherapy with Newcastle disease virus
Q Li (2017)
10.1200/JCO.2002.08.042
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.
A. Pecora (2002)
10.1080/21645515.2017.1412896
Talimogene laherparepvec: First in class oncolytic virotherapy
R. Conry (2018)
10.1016/j.virol.2014.06.014
ISG12a mediates cell response to Newcastle disease viral infection.
N. Liu (2014)
10.3892/IJO.32.4.777
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
M. Aigner (2008)
10.1016/j.actatropica.2018.04.007
Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Jeevanathan Kalyanasundram (2018)
10.1007/s00705-017-3411-4
Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)
K. Sharma (2017)
10.1186/s12929-016-0273-0
Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model
Ying An (2016)
10.1016/j.molonc.2015.10.016
In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Linda Hammerich (2015)
10.1111/j.1478-3231.2009.01971.x
Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice
Y. Li (2009)
10.1182/blood-2013-09-528851
Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity.
A. Castleton (2014)
10.1158/1078-0432.CCR-18-0220
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Kathy Matuszewska (2018)
10.1016/j.virusres.2009.10.020
The interferon antagonistic activities of the V proteins from two strains of Newcastle disease virus correlate with their known virulence properties.
Judith G. Alamares (2010)
10.4049/jimmunol.1004163
Type I IFNs Control Antigen Retention and Survival of CD8α+ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming
Silvia Lorenzi (2011)
10.3892/IJO.16.2.363
Newcastle disease virus activates macrophages for anti-tumor activity.
V. Schirrmacher (2000)
10.1158/1078-0432.CCR-09-1292
Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
Emily K Mader (2009)
10.3389/fonc.2014.00191
Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses
Nicole Forbes (2014)
10.1016/j.cell.2018.10.038
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
M. Sade-Feldman (2018)
10.1099/vir.0.000142
Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism.
Z. Zhang (2015)
10.1186/1471-2407-14-551
Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
K. Jiang (2014)
10.3892/ijo.2018.4661
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
V. Schirrmacher (2019)
10.1016/0008-8749(90)90302-8
Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
P. Hoegen (1990)
10.1200/JCO.2004.09.038
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
H. Steiner (2004)
Quo Vadis Cancer Therapy? Fascinating Discoveries of the Last 60 Years
V Schirrmacher (2017)
Newcastle disease. In Diseases of Poultry
P. J. Miller (2013)
10.3892/ijmm.2015.2213
Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review).
V. Schirrmacher (2015)
10.1038/sj.gt.3303026
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
M. Janke (2007)
The Biology of paramyxoviruses
S. Samal (2011)
10.1016/j.vetmic.2019.01.002
Syncytia generated by hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus induce complete autophagy by activating AMPK-mTORC1-ULK1 signaling>.
S. Ren (2019)
10.1093/NEUONC/NOY148.025
ATIM-30. HOW TO MONITOR IMMUNOGENIC CELL DEATH IN PATIENTS WITH GLIOBLASTOMA
S. Gool (2018)
10.4049/jimmunol.170.4.1814
TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus 1
B. Washburn (2003)
10.1146/annurev-immunol-110416-120628
Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
T. Waldmann (2017)
10.1038/sj.cgt.7700048
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules
C. Haas (1999)
10.1517/14712598.5.10.1303
Natural killer–dendritic cell cross-talk in cancer immunotherapy
P. Kalinski (2005)
10.3748/WJG.V9.I3.495
Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.
W. Liang (2003)
10.1182/BLOOD.V91.11.4311
Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells.
K. Chlichlia (1998)
10.1002/ijc.10781
Cognate interactions between memory T cells and tumor antigen‐presenting dendritic cells from bone marrow of breast cancer patients: Bidirectional cell stimulation, survival and antitumor activity in vivo
L. Bai (2003)
10.1038/ncomms14340
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
D. Zamarin (2017)
10.1128/JVI.01761-18
Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells
Xing Liu (2018)
10.1089/jir.2012.0095
The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling.
W. Ch’ng (2013)
Phase I/II trial of intravenous DNV-HUJ oncolytic virus in recurrent glioblastoma multiforme
A. I. Freeman (2006)
10.3892/ol.2014.2588
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
V. Schirrmacher (2014)
10.18632/oncotarget.13345
Newcastle disease virus employs macropinocytosis and Rab5a-dependent intracellular trafficking to infect DF-1 cells
L. Tan (2016)
10.1007/s00705-011-0987-y
Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus
J. Bian (2011)
Quo Vadis Cancer Therapy? Fascinating Discoveries of the Last 60 Years; Lambert
V. Schirrmacher (2017)
10.1016/j.immuni.2018.09.024
Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12
Christopher S Garris (2018)
10.1016/j.micpath.2018.12.047
Detection of viral components in exosomes derived from NDV-infected DF-1 cells and their promoting ability in virus replication.
Xiaohong Xu (2019)
10.3892/IJO.13.6.1105
Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.
C. Haas (1998)
10.1002/ijc.21821
Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence
C. Fiola (2006)
10.1016/J.TRANSPROCEED.2006.11.004
Cross-tolerance of recipient-derived transforming growth factor-beta dendritic cells.
M-M Tiao (2007)
10.1126/scitranslmed.aau0417
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
Praveen K Bommareddy (2018)
10.3892/IJO.24.3.623
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
P. Fournier (2004)
10.3892/IJO.21.1.85
Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis.
B. Washburn (2002)
10.1002/IJC.2910370416
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects
R. Heicappell (1986)
10.1002/EJI.1830231032
Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses
C. Ertel (1993)
10.1016/J.YMTHE.2005.08.016
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.
A. Freeman (2006)
10.4049/jimmunol.0804315
Cutting Edge: TLR-Dependent Viral Recognition Along with Type I IFN Positive Feedback Signaling Masks the Requirement of Viral Replication for IFN-α Production in Plasmacytoid Dendritic Cells1
Y. Kumagai (2009)
10.1016/j.coph.2017.05.006
Epigenetic modulation in cancer immunotherapy
S. Gallagher (2017)
10.1200/JCO.18.01010
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
S. Loi (2019)
10.1002/9780470344668.CH1
Newcastle Disease and Related Avian Paramyxoviruses
F. Leighton (2008)
10.1016/0022-4804(92)90310-V
Newcastle disease virus selectively kills human tumor cells.
K. Reichard (1992)
[Therapy of cancer].
C. DE BARBOSA N (1957)
10.3390/v8030072
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses
Ming Yuan (2016)
10.1038/mt.2013.51
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Ilkka Liikanen (2013)
10.1038/s41598-019-43668-8
A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma
Ali Sakhawat (2019)
10.3892/IJO.23.3.673
Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA.
P. Fournier (2003)
10.1016/j.cellimm.2014.03.016
Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells.
Andrea Sobo-Vujanovic (2014)
10.3892/IJO_00000070
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
M. Janke (2008)
10.1126/science.1253451
Whole-genome analyses resolve early branches in the tree of life of modern birds
E. Jarvis (2014)
10.1007/s00262-008-0526-1
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
T. Schulze (2008)
10.1038/nature25501
TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
S. Mariathasan (2018)
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus.
Jinyang Zeng (2002)
10.1126/scitranslmed.aam7577
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson (2018)
10.1038/sj.gt.3300787
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
V. Schirrmacher (1999)
10.1080/2162402X.2018.1503032
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
Jonathan G Pol (2018)
10.1016/j.immuni.2014.05.003
Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.
J. Crouse (2014)
Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
P. von Hoegen (1988)
10.1189/jlb.5RI0116-013RR
Combinatorial approach to cancer immunotherapy: strength in numbers
A. Vilgelm (2016)
10.4049/jimmunol.176.12.7288
IL-2 Is Required for the Activation of Memory CD8+ T Cells via Antigen Cross-Presentation1
N. Blachère (2006)
10.1007/s00432-017-2470-y
α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus
Q. Li (2017)
10.1016/S0304-3835(01)00617-6
Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration.
A. Phuangsab (2001)
10.1158/1078-0432.CCR-10-1114
Direct Effects of Type I Interferons on Cells of the Immune System
S. Hervas-Stubbs (2011)
10.3390/ijms18040878
EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer
J. Coy (2017)
10.1007/BF02987752
A ten-year follow-up on stage II Malignant Melanoma patients treated postsurgically with newcastle disease virus oncolysate
W. Cassel (1992)
Dearing and gemcitabine in patients with advanced cancer
(2011)
Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.
Lulu Hu (2015)
10.1016/j.gene.2018.08.069
A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapy.
A. Stepanenko (2018)
10.1158/0008-5472.CAN-16-2165
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.
L. Fend (2017)
10.1007/s00705-018-3745-6
Immune responses of mature chicken bone-marrow-derived dendritic cells infected with Newcastle disease virus strains with differing pathogenicity
B. Xiang (2018)
10.1007/BF01310936
In vivo interference by Newcastle disease virus in chickens, the natural host of the virus
X. Li (2005)
10.2217/imt.15.48
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report.
V. Schirrmacher (2015)
10.1155/2014/386470
Newcastle Disease Virus Interaction in Targeted Therapy against Proliferation and Invasion Pathways of Glioblastoma Multiforme
J. Abdullah (2014)
10.1186/s13287-016-0414-0
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL
G. Kazimirsky (2016)
10.1038/cgt.2013.78
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
P. Buijs (2014)
10.1016/j.vaccine.2017.07.032
Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine.
John P Graham (2017)
10.1126/SCIENCE.1132505
5'-Triphosphate RNA Is the Ligand for RIG-I
V. Hornung (2006)
10.1038/sj.cgt.7700109
Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells
C. Termeer (2000)
The Induction of Immunogenic Cell Death ( ICD ) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma ( GBM )
SW VanGool (2018)
10.1007/s11262-019-01637-3
The interferon antagonistic activities of the V proteins of NDV correlated with their virulence
Xinglong Wang (2019)
10.1016/j.jcyt.2018.05.009
Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium.
Yuriko Nishiyama-Fujita (2018)
10.1038/s41598-019-42004-4
Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs
Asuka Yoshida (2019)
10.1186/s13046-015-0271-1
Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice
D. Wei (2015)
Immune ckeckpoint modulation: Rational design of combinatorial strategies
D. Zamarin (2015)
The hemagglutinin-neuraminidase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB
Y. Liang (2017)
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy
E. K. Mader (2009)
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
V. Schirrmacher (1997)
10.1002/mabi.201700187
Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
E. M. Scott (2018)
10.1038/gt.2016.70
Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
E. Ilett (2017)
10.1186/s12885-019-5516-5
Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines
Juraimi Raihan (2019)
10.3892/IJO_00000796
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25.
P. Fournier (2010)
10.1128/JVI.00211-09
Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase
M. Jarahian (2009)
10.1128/JVI.00401-09
The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin
I. Lazar (2009)
10.1093/INTIMM/8.4.491
Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B.
V. Umansky (1996)
10.3892/IJO.27.2.377
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein.
H. Bian (2005)
10.1159/000328325
Apoptin Enhances the Oncolytic Properties of Newcastle Disease Virus
Yantao Wu (2011)
10.18632/oncotarget.17970
RIP1 is a central signaling protein in regulation of TNF-α/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection
Ying Liao (2017)
10.1158/1078-0432.CCR-10-2159
A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
M. Lolkema (2010)
10.1002/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V
Newcastle disease virus as an antineoplastic agent
W. Cassel (1965)
10.1586/14760584.2014.854169
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
V. Schirrmacher (2014)
10.3390/cancers11050651
Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses
Philipp Schuster (2019)
10.1016/j.dci.2018.12.006
Goose MAVS functions in RIG-I-mediated IFN-β signaling activation.
Y. Sun (2019)
10.2147/OTT.S185876
The progression of HMGB1-induced autophagy in cancer biology
Tianwei Xu (2019)
10.1128/JVI.00241-06
Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell Death
S. Elankumaran (2006)
Caspaseand p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus
J. Bian (2011)
10.1080/2162402X.2017.1407897
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.
Tiphaine Delaunay (2018)
10.1016/j.pharmthera.2015.01.003
Immune checkpoint modulation: rational design of combination strategies.
D. Zamarin (2015)
10.1586/erv.10.124
Use of attenuated paramyxoviruses for cancer therapy
Patrycja J. Lech (2010)
10.4049/jimmunol.0903453
Antiviral Response Dictated by Choreographed Cascade of Transcription Factors
Elena Zaslavsky (2010)
10.1002/ijc.31026
Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
T. Schwaiger (2017)
10.1371/journal.pone.0178746
The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB
Y. Liang (2017)
10.31557/APJCP.2019.20.3.757
Evaluation of Ultra-Microscopic Changes and Proliferation of Apoptotic Glioblastoma Multiforme Cells Induced by Velogenic Strain of Newcastle Disease Virus AF2240
Rola Ali-Saeed (2019)
10.1186/s40425-019-0632-y
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
Louise M. E. Müller (2019)
10.1158/1535-7163.MCT-14-0913
Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models
S. Cuadrado-Castano (2015)
10.1038/mt.2014.160
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
C. E. Engeland (2014)
10.1007/978-1-59745-561-9
Gene Therapy of Cancer
W. Walther (2009)
Gene Therapy of Cancer. Methods and Protocols
W. Walther (2000)
10.1083/jcb.201512012
Transcriptional determinants of tolerogenic and immunogenic states during dendritic cell maturation
B. Vander Lugt (2017)
10.1038/s41467-019-08557-8
Local unfolding of the HSP27 monomer regulates chaperone activity
T. Alderson (2019)
10.3390/cells7120278
Autophagy: An Essential Degradation Program for Cellular Homeostasis and Life
Yoomi Chun (2018)
10.3389/fonc.2014.00001
Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
T. Hellevik (2014)
10.1038/nri3581
Regulation of type I interferon responses
L. Ivashkiv (2013)
10.4161/21624011.2014.955687
Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer
M. Schnurr (2014)
Newcastle disease.
C. Cunningham (1947)
10.3390/ijms18051103
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
V. Schirrmacher (2017)
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
R. Lorence (2003)
CRISPR - Cas 9 as a powerful tool for efficient creation of oncolytic
M. Yuan (2016)
10.1016/j.vaccine.2010.08.011
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
J. Ni (2010)
10.1002/IJC.2910380514
Immunoresistant metastatic tumor variants can re‐express their tumor antigen after treatment with DNA methylation‐inhibiting agents
P. Altevogt (1986)
10.1371/journal.pone.0116550
Computational Analysis of an Autophagy/Translation Switch Based on Mutual Inhibition of MTORC1 and ULK1
P. Szymańska (2015)
10.1007/BF00184874
Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines
H. Kirchner (2004)
10.1038/s41577-018-0014-6
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K Bommareddy (2018)
10.1016/j.omto.2018.10.005
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
R. Havunen (2018)



This paper is referenced by
10.3390/cancers13040614
Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
Eftychia Stavrakaki (2021)
10.1038/s41434-020-0145-9
Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses
T. Liu (2020)
10.1080/14712598.2020.1729351
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Matthew Chiu (2020)
10.1080/14737140.2020.1785874
Position paper: new insights into the immunobiology and dynamics of tumor–host interactions require adaptations of clinical studies
Tobias Sprenger (2020)
10.3390/biomedicines8080237
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
V. Schirrmacher (2020)
10.22088/IJMCM.BUMS.8.3.211
Caspase Dependent and Independent Anti-hematological Malignancy Activity of AMHA1 Attenuated Newcastle Disease Virus
Mohammed S. Mohammed (2019)
10.3390/biomedicines9030293
Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications
V. Schirrmacher (2021)
10.1080/14712598.2020.1811848
Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy
Weijie Zhang (2020)
10.3389/fmicb.2019.00209
Inhibitor of Sarco/Endoplasmic Reticulum Calcium-ATPase Impairs Multiple Steps of Paramyxovirus Replication
N. Kumar (2019)
10.1155/2020/8814878
Modulated Electrohyperthermia: A New Hope for Cancer Patients
Huda F AlShaibi (2020)
10.1128/JVI.01677-19
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines
G. Vijayakumar (2019)
10.7488/ERA/523
Molecular mechanisms of oncolytic properties of Newcastle disease virus (NDV) in human cancer cells
Archana Chandrabhan Jadhav (2020)
10.4155/tde-2019-0076
Advances in delivery vectors for gene therapy in liver cancer.
Katherine E Redd Bowman (2019)
10.1016/j.omto.2018.02.001
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
N. Annels (2018)
10.3389/fnmol.2021.621831
Current Approaches for Glioma Gene Therapy and Virotherapy
K. Banerjee (2021)
10.2147/OTT.S185876
The progression of HMGB1-induced autophagy in cancer biology
Tianwei Xu (2019)
10.1016/j.omto.2018.10.005
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
R. Havunen (2018)
10.3390/biomedicines8030061
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
V. Schirrmacher (2020)
10.3390/biomedicines8030055
New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
V. Schirrmacher (2020)
10.3892/ol.2021.12499
Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy
Xianyao Wang (2021)
10.1007/s00262-020-02751-0
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution
R. Kleef (2020)
10.3390/biomedicines8110526
Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
V. Schirrmacher (2020)
10.3390/v12111305
Genomic Diversity and Evolution of Quasispecies in Newcastle Disease Virus Infections
A. Jadhav (2020)
10.3390/cancers12123552
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
Bharat Burman (2020)
10.3390/cells9061405
Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion
N. García-Romero (2020)
10.1111/febs.15536
Targeted modulation of E3 ligases using engineered ubiquitin variants
Nicole LeBlanc (2020)
Semantic Scholar Logo Some data provided by SemanticScholar